Market research
ARPO Aerpio Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- 0.0%
- Beta
- 1.65
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US00810B1052
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- 0.0%
- Beta
- 1.65
About
About Aerpio Pharmaceuticals Inc
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARPO discussion.
5 years, 4 months ago
Aerpio Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 85.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Aerpio Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 6.1% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Aerpio Pharmaceuticals, Inc gets an overall score of 3/5.